and P.A.; formal analysis, D.R.; investigation, R.B. cannot be concluded from the course of treatment, that (2) an increase in the dose and variability of outcome with treatment duration indicates the ongoing induction of NABs over time, that (3) the higher protein load of BoNT/A goes along with a higher incidence and prevalence of NAB induction and that (4) the best RGD (Arg-Gly-Asp) Peptides response to a BoNT/A is also dependent on the protein load of the preparation. test. Group size and parameters used always allowed the use of the em t /em -test. Both nonparametric and parametric testing yielded the same significant results (with slightly different levels of significance). The Pearson correlation coefficient was used for correlation analysis [12]. In the second study, switchers (SWI group) were split up according to the pre-treatment: the ABO group comprised all those patients who had initially been treated with aboBoNT/A, and the ONA group with all those with initial onaBoNT/A treatment. Furthermore, the AK-pos group contained all the MHDA-positive and the RGD (Arg-Gly-Asp) Peptides AK-neg group all the MHDA-negative patients. A one-way ANOVA with repeated measurements was calculated to compare the outcome measures ITSUI, BTSUI, STSUI, and ATSUI. For the comparison of the repeated measurements Greenhouse-Geisser tests were used. Furthermore, two to three group ANOVAs were performed to compare the ABO and ONA group and XEO-Mono group and to compare the AK-pos and AK-neg group and XEO-Mono group, respectively [33]. Acknowledgments The authors appreciate the excellent cooperation with Hans Bigalke and the staff of his Toxogen Laboratory (Hannover, Germany). Abbreviations BoNT/Abotulinum neurotoxin type ACDcervical dystoniaNABneutralizing antibodyaboBoNT/AabobotulinumonaBoNT/AonabotulinumtoxinincoBoNT/AincobotulinumtoxinTSUI scoreclinical score for evaluating cervical dystoniaMUmouse unituDUunified dose unitABantibodyPSTFpartial secondary treatment failureCSTFcomplete secondary treatment failureMHDAthe mouse hemidiaphragm testMVmean valueSDstandard deviationBTSUIbest outcome or best TSUI scoreITSUIinitial TSUI scoreELISAenzyme-linked immunosorbent assayVASvisual analogue scaleSWIswitchersCC grouppatients treated with a preparation containing complex proteins (ona- + abo group)CF grouppatients treated with preparation without complex proteins (inco group) Special Abbreviations First study: ABO grouppatients on aboBoNT/A monotherapyINCO grouppatients on incoBoNT/A monotherapyONA grouppatients on onaBoNT/A monotherapy Second study: abo grouppatients with switch from aboBoNT/A to incoBoNT/Aona grouppatients with switch from onaBoNT/A to incoBoNT/Ainco grouppatients on incoBoNT/A monotherapy Key Contribution (Running Title) Low antigenicity of RGD (Arg-Gly-Asp) Peptides incobotulinum toxin. Author Contributions Conceptualization, H.H. and S.S.; methodology, S.S. and H.H.; software, D.R.; validation, H.H., S.S., J.-I.L. and P.A.; formal analysis, D.R.; investigation, R.B. and B..; resources, B.. and R.B.; data curation, D.R.; writingoriginal draft preparation, S.S. and H.H.; writingreview and editing, S.S. and H.H.; visualization, S.S. and H.H.; supervision, P.A., H.H., J.-I.L. and S.S.; project administration, H.H.; funding acquisition, H.H. All authors have read and agreed to the published version of the manuscript. Financing The authors value the good support from the Inge-Diesbach-Stiftung. Charges for the MHDA-test of today’s research were included in a limited give to RGD (Arg-Gly-Asp) Peptides Harald Hefter from the Inge-Diesbach Stiftung. Issues appealing Harald Hefter continues to be supported with a limited grant from the Inge-Diesbach-Stiftung. This grant didn’t influence this content and design of today’s study. He declares no additional disclosures highly relevant to the manuscript. Sara Samadzadeh, Beyza rer, Raphaela Dietmar and Brauns Rosenthal declare no turmoil appealing. John-Ih Lee offers received honoraria for speaking/appointment from Bayer Health care, Boehringer Ingelheim, TRK Allergan, Novartis, Ipsen, Teva, and Daiichi-Sankyo aswell as travel grants or loans from Bayer Health care, Merz, Ipsen and Allergan beyond your posted function. Philipp Albrecht reviews grants or loans from Ipsen, grants or loans from Merz Pharmaceuticals, for NAB evaluation and tests of the info of individuals with spasticity, respectively, through the carry out from the scholarly research; grants or loans and personal charges from Allergan, grants or loans and personal charges from Biogen, grants or loans and personal charges from Merck, grants or loans and personal charges from Novartis, grants or loans and personal charges from Roche, personal charges from Teva, grants or loans, personal charges and nonfinancial support from Celgene, personal charges from Bayer Health care, grants or loans and personal charges from Sanofi Aventis, Genzyme, beyond your submitted work..

and P